Valneva (NASDAQ:VALN) Hits New 1-Year Low – Should You Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $5.04 and last traded at $5.3330, with a volume of 27494 shares trading hands. The stock had previously closed at $5.19.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on VALN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th. Guggenheim set a $11.00 price target on shares of Valneva in a report on Thursday, April 16th. The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a research note on Wednesday, April 22nd. Finally, Wall Street Zen raised shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $11.97.

Valneva Stock Performance

The company has a market capitalization of $492.57 million, a P/E ratio of -2.78 and a beta of 1.75. The firm has a 50 day moving average price of $5.63 and a two-hundred day moving average price of $7.87. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14.

Valneva (NASDAQ:VALN) last posted its earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. The company had revenue of $35.77 million for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. On average, research analysts expect that Valneva SE Sponsored ADR will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

Institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Valneva in the 4th quarter worth about $44,000. Marex Group plc acquired a new stake in shares of Valneva during the 2nd quarter worth about $64,000. XTX Topco Ltd bought a new position in Valneva during the 4th quarter valued at about $94,000. VSM Wealth Advisory LLC lifted its holdings in Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in Valneva in the third quarter valued at about $124,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.